Contact informationPlease contact Andreas Kleppe for more information
The Gray Level Entropy Matrix (GLEM), the backbone of Nucleotyping, was developed using a collection of tumor tissues from patients with advanced prostate cancer (SPCG-2), and increased entropy was shown to significantly correlate with poor survival.
Recently, a more advanced version of Nucleotyping was used to analyze a minimum of three blocks of prostate tumor from 314 patients, in the search for prognostic markers for relapse after surgery. We found distinct chromatin changes in the periphery of small nuclei, characteristic of patients with increased risk of relapse or cancer death. We have demonstrated that Nucleotyping is an independent prognostic marker with particular value for patients with a Gleason score of 7.